Simon Sturge

Simon John Sturge is the founder of Ligand UK Ltd., RiboTargets Ltd. Current positions include Executive Chairman at Mediar Therapeutics, Inc. since 2021, Chairman at Moonlake Immunotherapeutics AG since 2021, and Trustee at Weizmann UK.
Former roles include Chief Executive Officer & Director at Lonza Biologics Plc, Chief Executive Officer at Dr. Reddy's Research & Development BV from 2008 to 2011, Chief Executive Officer & Director at Kymab Ltd. from 2019 to 2021, Chief Executive Officer & Director at Kymab Group Ltd., Chairman-Supervisory Board at Cristal Delivery BV, Chairman at MoonLake Immunotherapeutics from 2022 to 2026, Director at Celltech Group Plc, Independent Non-Executive Director at Silence Therapeutics Plc from 2015 to 2016, Independent Non-Executive Director at Feedback Plc from 2017 to 2021, Independent Non-Executive Director at Galapagos NV from 2023 to 2025, Chief Operating Officer-Healthcare at Merck KGaA from 2013 to 2019, Manager-Business Development at Astra Pharmaceuticals Ltd., Senior Vice President at Boehringer Ingelheim BV from 2010 to 2013, and Chief Operating Officer at Merck Healthcare.
Education includes an undergraduate degree from the University of Sussex conferred in 1980.